SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-010719
Filing Date
2023-06-01
Accepted
2023-06-01 16:18:31
Documents
13
Period of Report
2023-05-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20230526x8k.htm   iXBRL 8-K 40878
2 EX-10.1 acrs-20230526xex10d1.htm EX-10.1 682828
  Complete submission text file 0001558370-23-010719.txt   959282

Data Files

Seq Description Document Type Size
3 EX-101.SCH acrs-20230526.xsd EX-101.SCH 3133
4 EX-101.LAB acrs-20230526_lab.xml EX-101.LAB 15914
5 EX-101.PRE acrs-20230526_pre.xml EX-101.PRE 10221
7 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20230526x8k_htm.xml XML 4840
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 23984927
SIC: 2834 Pharmaceutical Preparations